Development of a bioconjugate platform for modifying the immune response of autoreactive cytotoxic T lymphocytes involved in type 1 diabetes

Neha Nandedkar-Kulkarni[1], Abhishek R. Vartak[2], Steven J. Sucheck[2], Katherine A. Wall[1], Anthony Quinn[3], Michael P. Morran[1], and Marcia F. McInerney[1,4*]

[1] Department of Medicinal and Biological Chemistry ,University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Health Science Campus, 3000 Arlington Avenue, Toledo, Ohio 43614

[2] Department of Chemistry and Biochemistry, University of Toledo, College of Natural Sciences and Mathematics, Main Campus, 2801 West Bancroft Street, Toledo, Ohio 43606

[3] Department of Biological Sciences ,University of Toledo, College of Natural Sciences and Mathematics, Main Campus, 2801 West Bancroft Street, Toledo, Ohio 43606

[4] Center for Diabetes and Endocrine Research, University of Toledo, Health Science Campus, 3000 Arlington Avenue, Toledo, Ohio 43614

*E-mail: marcia.mcinerney@utoledo.edu

Supporting information is 10 pages and contains Figures S1-S9

List of Supporting Information Contents



Supplementary Figure S1. Effect of GAD546-554 peptide on CTL546.L clone cells at different time points. CTL.546.L cells were co-cultured with GAD546-554 pulsed irradiated M12C3.B7 B cells and evaluated for IFNγ release. Supernatants were harvested at the indicated times after stimulation. One way ANOVA followed by Tukey's multiple comparison test. n=3, ***$p \leq 0.01$. IFNγ release was normalized to untreated control.

Supplementary Figure S2. MALDI-MS data of azide terminated GAD 541-554 peptide **2**





Supplementary Figure S3. HPLC trace of azide terminated GAD 541-554 peptide **2**



Vydac C18 column was used with gradient elution (5-60% acetonitrile) with a single peak at 214 nm (solvent A = 0.085% TFA in water; solvent B = 98% acetonitrile and 0.085% TFA in water).

Supplementary Figure S4. MALDI-MS data of Pam_3CysSK_4 - GAD 541-554 peptide conjugate **2a**





Supplementary Figure S5. MALDI-MS data of de-protected Pam_3CysSK_4 - GAD 541-554 peptide conjugate **2b**





Supplementary Figure S6. MALDI-MS data for azide terminated altered peptide ligand (APL) **3**





Supplementary Figure S7. HPLC trace of azide terminated altered peptide ligand (APL) **3**



Vydac C18 column was used with gradient elution (5-60% acetonitrile) with a single peak at 214 nm (solvent A = 0.085% TFA in water; solvent B = 98% acetonitrile and 0.085% TFA in water).

Supplementary Figure S8. MALDI-MS data of Pam_3CysSK_4 - APL conjugate **3a**





Supplementary Figure S9. MALDI-MS data of de-protected Pam_3CysSK_4 - APL conjugate **3b**